NEW YORK, NY--(Marketwire -03/02/12)- Biotechnology shares have been on impressive run of late. Led by the growing popularity in early stage biotechnology companies, the iShares Nasdaq Biotechnology Index Fund is up roughly 20 percent over the last three months. A recent survey from BIO Industry Analysis finds that investors are more focused on early stage companies than later. "And, this sentiment is also borne out by the increase in percentage of investors who indicate that they are willing to invest in small market cap biotechs," Alan Eisenberg, executive vice president of emerging companies and business development, explained. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on ImmunoCellular Therapeutics Ltd. (OTC.BB: IMUC.OB - News) and Human Genome Sciences, Inc. (NASDAQ: HGSI - News). Access to the full company reports can be found at:
Biotech firms continue to negotiate a more challenging regulation process. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
ImmunoCellular Therapeutics, Ltd., a development stage company, focuses on developing and commercializing therapeutics to treat cancer using the immune system. Earlier this week the company entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma.
Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Earlier this week the company reported $25.7 million in sales of Benlysta for the period that ended Dec. 31 -- $29.1 million, excluding adjustments. U.S. regulators approved the drug in March, and European Union regulators did the same in July.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer